The US, UK, and China grapple with a resurgence of COVID-19 cases, highlighting worries about the Pirola or BA.2.86 variant. CDC flags this variant as higher-risk due to its widespread infections. Despite being milder than the initial strain, it’s distinct with 35 mutations. Pirola’s impact on survivors and vaccine recipients is a concern, suggesting higher susceptibility to breakthrough infections. The Pirola variant’s symptoms include rashes, conjunctivitis, and diarrhea. Detected globally, this WHO-designated variant poses worries of immune evasion and reduced vaccine efficacy, adding complexity to the ongoing pandemic.
Facts/Terms for UPSC Prelims
- Pirola or BA.2.86 Variant: A new strain of COVID-19 with 35 mutations, causing concerns about immune evasion and vaccine efficacy, and demonstrating distinct symptoms like rashes, conjunctivitis, and diarrhea.
- CDC: The Centers for Disease Control and Prevention, a US agency responsible for public health and safety, identifying, and responding to health threats.
- Immune Evasion: The ability of a variant to escape the immune response generated by prior infection or vaccination, potentially reducing their effectiveness against the new variant.